

PRESS RELEASE

August 25, 2021

CombiGene applies for international patent protection for the vectors developed within the CGT2 project

CombiGene announces today that the company has submitted a so-called PCT application to protect the vectors being developed within the lipodystrophy project CGT2. The Patent Cooperation Treaty (PCT) is an international agreement that allows companies to seek patent protection internationally for their inventions, covering approximately 150 countries with one single application. Under the framework of the PCT, a preliminary assessment of patentability will be provided before the application proceeds to the national phase in which national patent applications are filed. PCT applications are handled by the World Intellectual Property Organization (WIPO), a self-funding agency of the United Nations.

The now submitted PCT application builds on the UK patent application filed last year and is a natural next step in ensuring adequate patent protection for the lipodystrophy project CGT2.

“The PCT application is important to protect the work we have put into the project so far in a cost-effective way” says **Annika Ericsson**, Preclinical Project Manager at CombiGene. “Through the PCT application, we can also, in a second step, receive a report from WIPO on the novelty, inventiveness and industrial applicability of our vectors.”

About CGT2

The goal of the CGT2 project is to develop a gene therapy treatment for partial lipodystrophy, a rare disease characterized by altered fat distribution on the body. Patients suffer from body fat atrophy. In the absence of normal body fat, various organs begin to accumulate fat, leading on to serious metabolic complications, including extreme insulin resistance, hypertriglyceridemia (elevated values of blood fat triglyceride) and liver steatosis (fatty liver). There are currently a few symptom-relieving treatments for lipodystrophy, but no therapy that targets the root cause of the disease. For patients suffering from partial lipodystrophy, there are currently no treatments at all.

Eurostars Programme



CombiGene's project CGT2 is supported by the Eurostars Programme.
Project ID: 114714

About CombiGene AB

CombiGene's vision is to offer patients affected by severe life-changing diseases opportunities for a better life through innovative gene therapies. CombiGene's business concept is to develop effective gene therapies for serious diseases that today lack adequate treatment methods. Research assets are taken in from a network of external researchers and developed further up to clinical concept verification. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while CombiGene may drive the development and commercialization in-house for medicines aimed at limited patient populations. The company is public and listed on the Nasdaq First North Growth Market and the company's Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99, info@fnca.se.

For more information:

CombiGene AB (publ)
Jan Nilsson, CEO
Tel: +46 (0)704 66 31 63
jan.nilsson@combigene.com

Bert Junno, Chairman of the Board
Tel: +46(0) 70 7 77 22 09
bert.junno@combigene.com

Please read INGENEIOUS, a newsletter from CombiGene which contains general news and information that is judged not to have a significant effect on the share price. INGENEIOUS and press releases are available at www.combigene.com